Cellectis said it is quitting CAR-T programs and shifting resources toward ‘in vivo’ gene editing after assessing a changing competitive and development landscape. The company’s decision includes offloading lead programs rather than continuing to build internal CAR-T assets. The pivot reinforces a broader bet on delivering genetic payloads directly inside the body, where sponsors aim to reduce manufacturing complexity versus donor-derived or ex vivo cell therapies. For Cellectis, the move also signals capital reallocation toward longer-term platform development. With CAR-T space crowded by multiple modalities and increasingly demanding manufacturing and trial expectations, Cellectis’ shift may accelerate the company’s timeline for next-generation in vivo capabilities.